OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chu on the Importance of Identifying MSI Status in mCRC

October 14th 2020

Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.

Dr. Nazha on the Potential Role of Ropeginterferon Alfa-2b in Polycythemia Vera

October 14th 2020

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.

Dr. Maki on the Potential Utility of Immunotherapy in Sarcoma

October 14th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the potential utility of immunotherapy in sarcoma.

Dr. Bhat on Emerging Targeted Therapies in CLL

October 14th 2020

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Dr. Hussain on Rationale to Explore Relationship Between PSA and Outcomes in Nonmetastatic CRPC

October 13th 2020

Maha Hussain, MD, FACP, FASCO, discusses the design of the phase 3 PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Galligan the Utility of Up-front High-Intensity Therapy in Multiple Myeloma

October 13th 2020

Derek C. Galligan, MD, discusses the utility of up-front high-intensity therapy for patients with multiple myeloma.

Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic Malignancies

October 13th 2020

Nicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.

Dr. Paplomata on Managing Trastuzumab Deruxtecan–Induced ILD in HER2+ Breast Cancer

October 13th 2020

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Dr. Silbermann on the Role of Disease Biology in Multiple Myeloma

October 13th 2020

Rebecca Silbermann, MD, MMS, discusses the role of disease biology in multiple myeloma.

Dr. Davids on Selecting Between Continuous and Time-Limited Therapy in CLL

October 13th 2020

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

Dr. Farrington on the Importance of Genetic Testing in CRC

October 13th 2020

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast Cancer

October 13th 2020

Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.

Dr. Rampal on Tools to Estimate Prognosis in Myelofibrosis

October 13th 2020

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Dr. Martin on the Need for Head-to-Head Comparisons of BTK Inhibitors in MCL

October 12th 2020

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Dr. Bakouny on the Rate of Disease Progression in Sarcomatoid Carcinoma

October 12th 2020

Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.

Dr. Hill on Future Research With CAR T-Cell Therapy in B-Cell Lymphomas

October 12th 2020

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

October 12th 2020

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Dr. McDermott on the Next Steps of the DASL-HiCAP Trial in High-Risk Prostate Cancer

October 12th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.

Dr. O’Regan on the Risk of Cardiomyopathy With Trastuzumab in HER2+ Breast Cancer

October 12th 2020

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

Dr. Tseng on the Significance of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 9th 2020

William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.